Table 1. Clinical characteristics of... | American Society of Hematology

Table 1.

Clinical characteristics of patients with SS (n = 24) at blood sampling

SS case	Interval diagnosis to study inclusion, mo	Age at sample inclusion, y	WBC × 10⁹/L (Sysmex)	Treatment at blood sampling	Status last follow-up
1	6	75	9.2	Topical therapy	D+
2	44	64	7.8	Topical therapy	A+
3	15	61	6.6	Topical therapy, PUVA	A+
FU1*	35	63	6.5	Topical therapy
FU2	50	64	16.5	Topical therapy, MTX, prednisone
4	22	68	6.0	Topical therapy	A+
5	23	85	9.0	Topical therapy	D+
6	15	72	14.9	Topical therapy, prednisone	A+
FU1	34	74	11.9	Emollients
7	32	79	9.8	Topical therapy, prednisone	D+
8†	0	66	10.7	Topical therapy	A+
FU1	10	67	10.8	Topical therapy
FU2*	17	67	10.5	Topical therapy
FU3	30	68	10.4	Topical therapy, PUVA
9	46	77	5.7	Topical therapy, MTX	A+
FU1	66	78	10.9	Topical therapy, prednisone, TSI
10†	0	65	15.3	Prednisone	D+
11	6	61	4.8	PUVA, IFN-α	A+
FU1	16	62	25.7	Resminostat, CHOEP
FU2	25	62	4.5	Prednisone, mogamulizumab, gemcitabin
12†	0	82	7.9	Topical therapy, prednisone	A+
FU1	18	84	7.3	Topical therapy, prednisone, mogamulizumab
13†	0	57	11.5	Bath-PUVA	A+
FU1	6	57	11.9	Topical therapy, bath-PUVA	A+
14†	0	80	115.8	Chlorambucil	D+
15	68	69	10.7	Emollients	D+
16	2	67	11.7	Topical therapy, IFN-α, prednisone	A+
FU1	9	67	10.8	Topical therapy, IFN-α, prednisone
FU2	15	68	13.7	Topical therapy, prednisone, mogamulizumab
17*,†	0	77	7.4	Topical therapy	A+
18	20	68	16.2	CHOP, topical therapy	A+
19	130	72	6.0	CHOP	D+
20†	0	59	5.8	Topical therapy, ciclosporin, bleach bath	A+
21	4	73	14.1	Emollients	A+
22	1	61	11.2	Topical therapy, prednisone, UVB	A+
23†	0	52	10.4	Prednisone	A+
24	21	83	8.9	Topical therapy, prednisone	A+

SS case	Interval diagnosis to study inclusion, mo	Age at sample inclusion, y	WBC × 10⁹/L (Sysmex)	Treatment at blood sampling	Status last follow-up
1	6	75	9.2	Topical therapy	D+
2	44	64	7.8	Topical therapy	A+
3	15	61	6.6	Topical therapy, PUVA	A+
FU1*	35	63	6.5	Topical therapy
FU2	50	64	16.5	Topical therapy, MTX, prednisone
4	22	68	6.0	Topical therapy	A+
5	23	85	9.0	Topical therapy	D+
6	15	72	14.9	Topical therapy, prednisone	A+
FU1	34	74	11.9	Emollients
7	32	79	9.8	Topical therapy, prednisone	D+
8†	0	66	10.7	Topical therapy	A+
FU1	10	67	10.8	Topical therapy
FU2*	17	67	10.5	Topical therapy
FU3	30	68	10.4	Topical therapy, PUVA
9	46	77	5.7	Topical therapy, MTX	A+
FU1	66	78	10.9	Topical therapy, prednisone, TSI
10†	0	65	15.3	Prednisone	D+
11	6	61	4.8	PUVA, IFN-α	A+
FU1	16	62	25.7	Resminostat, CHOEP
FU2	25	62	4.5	Prednisone, mogamulizumab, gemcitabin
12†	0	82	7.9	Topical therapy, prednisone	A+
FU1	18	84	7.3	Topical therapy, prednisone, mogamulizumab
13†	0	57	11.5	Bath-PUVA	A+
FU1	6	57	11.9	Topical therapy, bath-PUVA	A+
14†	0	80	115.8	Chlorambucil	D+
15	68	69	10.7	Emollients	D+
16	2	67	11.7	Topical therapy, IFN-α, prednisone	A+
FU1	9	67	10.8	Topical therapy, IFN-α, prednisone
FU2	15	68	13.7	Topical therapy, prednisone, mogamulizumab
17*,†	0	77	7.4	Topical therapy	A+
18	20	68	16.2	CHOP, topical therapy	A+
19	130	72	6.0	CHOP	D+
20†	0	59	5.8	Topical therapy, ciclosporin, bleach bath	A+
21	4	73	14.1	Emollients	A+
22	1	61	11.2	Topical therapy, prednisone, UVB	A+
23†	0	52	10.4	Prednisone	A+
24	21	83	8.9	Topical therapy, prednisone	A+

Follow-up status of each patient is given as alive (A+) or died (D+) with SS.

CHOP, cyclophosphamide doxorubicin (Adriamycin) vincristine (Oncovin) prednisolone; FU, follow-up; IFN, interferon; PUVA, psoralen and UV light A; TSI, total skin electron irradiation; UVB, UV B; WBC, white blood cell.

In parallel, FACS experiment performed.

†

PB sample collected at the diagnostic stage.

View Large

This Feature Is Available To Subscribers Only